https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-announces-new-employment-inducement-grants-20261009 BiopharmaWatch en 2026-10-09T20:35:00.000Z Arcus Biosciences Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/CCEL/cryo-cell-reports-fiscal-q3-2026-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EVH/evolent-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-09T20:30:00.000Z Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026 https://www.biopharmawatch.com/news/AEON/aeon-biopharma-inducement-grant-nyse-american BiopharmaWatch en 2026-10-09T20:15:29.000Z AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 https://www.biopharmawatch.com/news/PCVX/vaxcyte-closes-1-15-billion-offerings BiopharmaWatch en 2026-10-09T20:05:09.000Z Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes https://www.biopharmawatch.com/news/ACH/accendra-health-nyse-listing-standard-notice BiopharmaWatch en 2026-10-09T20:05:00.000Z Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-announces-inducement-grants-nasdaq-listing-rule-5635-c BiopharmaWatch en 2026-10-09T20:05:00.000Z Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ASTH/astrana-health-q3-financial-results-2026 BiopharmaWatch en 2026-10-09T20:05:00.000Z Astrana Health, Inc. Schedules 2026 Third Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/AGEN/agenus-participate-chardan-healthcare-conference BiopharmaWatch en 2026-10-09T19:23:00.000Z Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference https://www.biopharmawatch.com/news/VRTX/vertex-alytfrek-data-north-american-cystic-fibrosis-conference BiopharmaWatch en 2026-10-09T17:15:00.000Z Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference https://www.biopharmawatch.com/news/BIAF/wallachbeth-capital-announces-closing-bioaffinity-technologies-4-million-registered-direct BiopharmaWatch en 2026-10-09T16:30:00.000Z WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/RGNT/regentis-biomaterials-thinkequity-conference-2026 BiopharmaWatch en 2026-10-09T16:05:00.000Z Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-inc-announces-closing-4-million-registered-direct-financing BiopharmaWatch en 2026-10-09T15:37:00.000Z bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules